Summary & Overview

Spinal Fusion Except Cervical with MCC: Inpatient Reimbursement Overview

DRG 456 covers noncervical spinal fusion procedures performed for spinal curvature, malignancy, infection, or extensive multilevel fusions when a Major Complication or Comorbidity is present, reflecting high clinical complexity. This group matters for inpatient reimbursement because its higher resource intensity and increased payment weight are driven by the underlying diagnoses, procedure extent, and documented Major Complication or Comorbidity.

Spinal Fusion Except Cervical with Spinal Curvature, Malignancy, Infection or Extensive Fusions with MCCDRG Spinal Fusion Except Cervical with Spinal Curvature, Malignancy, Infection or Extensive Fusions with MCCDRG 456Diagnosis-Related GroupInpatient ReimbursementMedicareSpine SurgeryOrthopedicsNeurosurgeryComplex Spine Procedures

DRG 456 Overview

DRG 456 covers inpatient admissions for noncervical spinal fusion procedures performed in the setting of spinal curvature, malignancy, infection, or unusually extensive fusion procedures when a Major Complication or Comorbidity is present. This Diagnosis-Related Group captures high-complexity surgical spine cases with elevated resource use driven by longer operative time, greater implant and implant-related costs, and increased perioperative management needs. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases the relative weight and payment rate compared with less complex spinal fusion groups. Accurate coding of the underlying diagnoses, procedure extent, and Major Complication or Comorbidity is essential to assigning the correct Diagnosis-Related Group and associated inpatient reimbursement.

Clinical Trials

Acute perioperative optimization and complication mitigation trials: Studies focusing on interventions during the index hospitalization to reduce perioperative morbidity and mortality for patients undergoing non-cervical spinal fusion with spinal deformity, malignancy, infection, or multilevel/complex fusion with major complications (MCC). These trials enroll high-risk inpatients (often older adults, immunocompromised patients, or those with metastatic spine disease or spinal infection) and test protocols such as enhanced hemodynamic monitoring, infection-control bundles, blood-conservation strategies, or timing/selection of operative staging. Results are directly relevant to providers managing immediate surgical risk and to payers because successful protocols can reduce intensive care use, returns to the OR, and prolonged length of stay associated with this DRG.
Comparative effectiveness studies of surgical approaches and implant strategies: Pragmatic trials or registry-based comparative studies that evaluate different fusion techniques (e.g., posterior-only versus combined anterior-posterior approaches), extent of fusion constructs, use of augmentation for osteoporotic bone, or choice of instrumentation in patients with spinal curvature, tumor-related instability, or infection-related destruction. These studies target heterogeneous inpatient cohorts within this DRG to determine which approaches yield superior short-term clinical outcomes (complication rates, neurological preservation), resource utilization (operative time, transfusions), and 30–90 day readmission profiles. Findings inform surgeons and hospital administrators about value-based choices of technique and implants and help payers assess procedure-related cost-effectiveness and appropriate bundling for reimbursement.
Post-discharge functional recovery and readmission prevention research: Prospective cohort studies and interventional trials assessing early rehabilitation protocols, coordinated home health strategies, or outpatient surveillance programs for patients discharged after complex non-cervical fusion for deformity, malignancy, or infection. These studies enroll patients at discharge or within the first 30 days and measure functional recovery, wound healing, opioid and pain outcomes, and readmissions for infection or instrumentation failure. The evidence guides care pathways that can shorten downstream utilization, improve functional outcomes for this high-risk DRG population, and provide payers with data to support post-acute care coverage decisions and risk-adjusted payment models.

Related Codes

506-MAJOR-THUMB-OR-JOINT-PROCEDURES

Major Thumb or Joint Procedures: Inpatient Reimbursement Overview

474-AMPUTATION-FOR-MUSCULOSKELETAL-SYSTEM-AND-CONNECTIVE-TISSUE-DISORDERS-WITH-MCC

Amputation for Musculoskeletal System and Connective Tissue Disorders with MCC: Inpatient Reimbursement Overview

448-MULTIPLE-LEVEL-SPINAL-FUSION-EXCEPT-CERVICAL-WITHOUT-MCC

Multiple Level Spinal Fusion Except Cervical without MCC: Inpatient Reimbursement Overview

496-LOCAL-EXCISION-AND-REMOVAL-OF-INTERNAL-FIXATION-DEVICES-EXCEPT-HIP-AND-FEMUR-WITH-CC

Local Excision and Removal of Internal Fixation Devices Except Hip and Femur with CC: Inpatient Reimbursement Overview

479-BIOPSIES-OF-MUSCULOSKELETAL-SYSTEM-AND-CONNECTIVE-TISSUE-WITHOUT-CC-MCC

Biopsies of Musculoskeletal System and Connective Tissue without CC/MCC: Inpatient Reimbursement Overview

563-FRACTURE-SPRAIN-STRAIN-AND-DISLOCATION-EXCEPT-FEMUR-HIP-PELVIS-AND-THIGH-WITHOUT-MCC

Fracture, Sprain, Strain and Dislocation Except Femur, Hip, Pelvis and Thigh without MCC: Inpatient Reimbursement Overview

466-REVISION-OF-HIP-OR-KNEE-REPLACEMENT-WITH-MCC

Revision of Hip or Knee Replacement with MCC: Inpatient Reimbursement Overview

472-CERVICAL-SPINAL-FUSION-WITH-CC

Cervical Spinal Fusion with CC: Inpatient Reimbursement Overview

488-KNEE-PROCEDURES-WITHOUT-PRINCIPAL-DIAGNOSIS-OF-INFECTION-WITH-CC-MCC

Knee Procedures without Principal Diagnosis of Infection with CC/MCC: Inpatient Reimbursement Overview

559-AFTERCARE-MUSCULOSKELETAL-SYSTEM-AND-CONNECTIVE-TISSUE-WITH-MCC

Aftercare, Musculoskeletal System and Connective Tissue with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 104

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.